FOLH1 and neoplasm: Radiotracers containing ABM have been developed as theranostic probes targeting tumor-expressing molecules such as PSMA, SSTR, αvβ3 integrin, folate receptor, glucagon-like peptide-1 receptor and bone [105, 155–157].